Erstlinienchemotherapie beim Harnblasenkarzinom

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Der Onkologe

• Publication date

  2012-10-27

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00761-012-2325-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

  2012cited by this paper
• Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

  2012cited by this paper
• Under-representation of older adults in cancer registration trials: known problem, little progress.

  2012cited by this paper
• A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

  2011cited by this paper
• Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

  2009cited by this paper
• The updated EAU guidelines on muscle-invasive and metastatic bladder cancer.

  2009cited by this paper
• Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

  2006cited by this paper
• Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder

  2006cited by this paper
• Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.

  2005cited by this paper
• Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

  2005cited by this paper
• The phase III candidate: can we improve the science of selection?

  2004cited by this paper
• Effects of cancer history and comorbid conditions on mortality and healthcare use among older cancer survivors

  2004cited by this paper
• Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

  2002cited by this paper
• Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

  2001cited by this paper
• Metastatic Urothelial Cancer: Evaluation of Prognostic Factors and Change in Prognosis during the Last Twenty Years

  2001cited by this paper
• Management of cancer in the older person: a practical approach.

  2000cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper

• Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

  2013cites this paper
• Systemische Therapie des metastasierten Blasenkarzinoms

  2013cites this paper